BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ for PLASMA PROTEIN THERAPEUTICS ASSOCIATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 19, 2016 | $30,000 | Replaced |
| 1st Quarter - Termination | Jan 26, 2017 | $30,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICOLE CARELLI | — |
| SARA LOVE RAWLINGS New | Senate Appropriations Committee |
| CAROLINE SELBY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.